Nanobiotix S.A.
Nanobiotix S.A. (NANO.PA) Stock Overview
Explore Nanobiotix S.A.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
209.6M
P/E Ratio
-6.26
EPS (TTM)
$-1.44
ROE
0.77%
NANO.PA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Nanobiotix S.A. (NANO.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.26 and a market capitalization of 209.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Laurent Levy
108
60 rue de Wattignies, Paris
2012